Document is current
Any future updates will be listed below
-
Authors
Kondrup, Karoline https://orcid.org/0000-0003-0602-5981
Iisager, Laura
Salachan, Paul Vinu https://orcid.org/0000-0002-8179-5989
Nørgaard, Maibritt https://orcid.org/0000-0002-9626-6510
Lamy, Philippe
Eeles, Rosalind https://orcid.org/0000-0002-3698-6241
Hansen, Torben Frøstrup https://orcid.org/0000-0001-7476-671X
Osther, Palle Jörn Sloth
Zedan, Ahmed Hussein
Borre, Michael https://orcid.org/0000-0002-1519-9185
Sørensen, Karina Dalsgaard https://orcid.org/0000-0002-4902-5490
-
Funding
Funding for this research was provided by:
Health Research Fund of Central Denmark Region
Dansk Kræftforsknings Fond
Graduate School of Health, Aarhus University, Denmark
Novo Nordisk Fonden
- License Information
-
More Information
Article History
Received: 7 October 2025
Revised: 25 February 2026
Accepted: 24 March 2026
First Online: 10 April 2026
Competing interests
: RE has received honoraria from GU-ASCO, Janssen, University of Chicago, Dana Farber Cancer Institute USA as a speaker, as well as educational honorarium from Bayer and Ipsen. RE is a member of an external expert committee to AstraZeneca UK, the Active Surveillance Movember Committee, and the SAB of Our Future Health. RE undertakes private practice as a sole trader at The Royal Marsden NHS Foundation Trust and 90 Sloane Street SW1X 9PQ and 280 Kings Road SW3 4NX, London, UK.
: All research forming the basis of this study was conducted in accordance with relevant rules, regulations, and guidelines and conform to the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants prior to their donation of plasma samples for a research biobank (approved by The Central Denmark Region Committees on Health Research Ethics [jr. nr. 2000-0299], The Southern Denmark Region Committees on Health Research Ethics [S-20160029], and The Danish Data Protection Agency [jr. nr. 2013-41-2041, jr. nr. 2007-58-0010, and jr. nr. 17/34479]). The present study was approved by the Danish National Committee on Health Research Ethics [jr. nr. 1302791 and jr. nr. 1603542], who waived the requirement for patient consent, as (1) the new analyses were considered to not pose any health risk or other significant disadvantages to the participants and (2) an expert committee was established to deal with potential (although unlikely) incidental genetic findings in this new study.
